{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Injection+4+mcg%2FmL", "query": { "intervention": "Placebo Injection 4 mcg/mL" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Injection+4+mcg%2FmL&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T20:09:29.982Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07675629", "title": "Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Prevention" ], "interventions": [ { "name": "PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C))", "type": "BIOLOGICAL" }, { "name": "PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E))", "type": "BIOLOGICAL" }, { "name": "Alhydrogel adjuvant", "type": "BIOLOGICAL" }, { "name": "GLA-SE adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA Vaccines, Protein Vaccines and Adjuvants", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Worcester HIV Vaccine", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 126, "start_date": "2026-09-01", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-09-11T20:09:29.982Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07675629" }, { "nct_id": "NCT02852005", "title": "Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "MVA/HIV62B vaccine", "type": "BIOLOGICAL" }, { "name": "AIDSVAX B/E vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 27, "start_date": "2017-01", "completion_date": "2019-10-29", "has_results": true, "last_update_posted_date": "2022-08-08", "last_synced_at": "2026-09-11T20:09:29.982Z", "location_count": 7, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02852005" }, { "nct_id": "NCT03383588", "title": "Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pain, Referred" ], "interventions": [ { "name": "Bupivacaine", "type": "DRUG" }, { "name": "Morphine", "type": "DRUG" }, { "name": "Fentanyl", "type": "DRUG" }, { "name": "Epinephrine", "type": "DRUG" }, { "name": "Saline solution", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "17 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "17 Years to 40 Years · Female only" }, "enrollment_count": 26, "start_date": "2018-07-19", "completion_date": "2018-12-31", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-09-11T20:09:29.982Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03383588" }, { "nct_id": "NCT04492475", "title": "Adaptive COVID-19 Treatment Trial 3 (ACTT-3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Remdesivir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 969, "start_date": "2020-08-05", "completion_date": "2020-12-21", "has_results": true, "last_update_posted_date": "2022-03-14", "last_synced_at": "2026-09-11T20:09:29.982Z", "location_count": 55, "location_summary": "Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04492475" }, { "nct_id": "NCT02496221", "title": "A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Albiglutide 50 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "CCK (Kinevac)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2015-06-11", "completion_date": "2015-10-13", "has_results": true, "last_update_posted_date": "2018-04-05", "last_synced_at": "2026-09-11T20:09:29.982Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02496221" }, { "nct_id": "NCT02788045", "title": "Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.Mos.HIV", "type": "BIOLOGICAL" }, { "name": "Ad26.Mos4.HIV", "type": "BIOLOGICAL" }, { "name": "Clade C gp140", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 201, "start_date": "2016-07-08", "completion_date": "2022-04-25", "has_results": true, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-09-11T20:09:29.982Z", "location_count": 9, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02788045" }, { "nct_id": "NCT02972424", "title": "PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteoporotic Fractures" ], "interventions": [ { "name": "Teriparatide Prefilled Syringe", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hospital for Special Surgery, New York", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 35, "start_date": "2017-05-01", "completion_date": "2021-07-08", "has_results": true, "last_update_posted_date": "2022-07-27", "last_synced_at": "2026-09-11T20:09:29.982Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02972424" }, { "nct_id": "NCT00111605", "title": "Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "HIV-1 gag DNA", "type": "BIOLOGICAL" }, { "name": "HIV-1 gag DNA plus IL-12 DNA adjuvant", "type": "BIOLOGICAL" }, { "name": "CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine)", "type": "BIOLOGICAL" }, { "name": "Sodium chloride injection (0.9%)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 144, "start_date": null, "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-09-11T20:09:29.982Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00111605" }, { "nct_id": "NCT00500747", "title": "Chiron Corp HCV E1/E2 Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "HCV E1E2/MF59", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 60, "start_date": "2003-08", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2011-06-10", "last_synced_at": "2026-09-11T20:09:29.982Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00500747" }, { "nct_id": "NCT03789318", "title": "Study in Subjects Undergoing Complete Abdominoplasty", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Postsurgical Pain" ], "interventions": [ { "name": "CA-008 5 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Bupivacaine Hydrochloride", "type": "DRUG" }, { "name": "Hydromorphone", "type": "DRUG" }, { "name": "Fentanyl", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Oxycodone", "type": "DRUG" }, { "name": "CA-008 10 mg", "type": "DRUG" }, { "name": "CA-008 15 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Concentric Analgesics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 54, "start_date": "2018-12-03", "completion_date": "2019-06-12", "has_results": true, "last_update_posted_date": "2024-03-19", "last_synced_at": "2026-09-11T20:09:29.982Z", "location_count": 1, "location_summary": "Pasadena, California", "locations": [ { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03789318" } ] }